Vir Biotechnology
213 hedge funds and large institutions have $558M invested in Vir Biotechnology in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 83 increasing their positions, 60 reducing their positions, and 42 closing their positions.
97% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $961K
38% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 60
12.13% more ownership
Funds ownership: 68% → 80.13% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less capital invested
Capital invested by funds: $604M → $558M (-$46M)
9% less funds holding
Funds holding: 233 → 213 (-20)
45% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$69.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.91M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.2M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.67M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.24M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.02M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.53M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.52M |
| 5 |
BlackRock
New York
|
-$2.08M |
VIR Hedge Fund Activity: Q2 2025 in Review
213 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2025, worth a combined $558M — down 7.6% from $604M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of VIR and 23 opened new positions — a net loss of 19 holders — while 60 trimmed existing stakes and 83 added.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $69.3M. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.24M sold.
- 213 institutional investors held Vir Biotechnology (VIR) as of Q2 2025, down from 233 in Q1 2025.
- Funds reported $558M of Vir Biotechnology stock for Q2 2025, down 7.6% quarter-over-quarter.
- 23 funds opened new Vir Biotechnology positions in Q2 2025 and 42 closed out, a net change of -19 holders.
- The largest Vir Biotechnology buyer in Q2 2025 was Arch Venture Management, an estimated $69.3M added.
- The largest Vir Biotechnology seller in Q2 2025 was Tang Capital Management, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2025.